10-Q: Cognition Therapeutics Advances Pipeline, Boosts Cash

Cognition Therapeutics reported positive Phase 2 data for zervimesine in DLB and GA, alongside a significant capital raise, extending its cash runway into Q2 2027.

Summary

• Net loss for the nine months ended September 30, 2025, improved to $20.1 million from $26.1 million in the prior year.
• Research and development expenses decreased by $7.5 million to $26.0 million for the nine months ended September 30, 2025, primarily due to reduced Phase 2 trial activities.
• General and administrative expenses decreased by $1.6 million to $8.1 million for the nine months ended September 30, 2025.
• Grant income decreased to $13.4 million for the nine months ended September 30, 2025, from $16.5 million in the prior year.
• Cash and cash equivalents increased to $39.3 million as of September 30, 2025, from $25.0 million at December 31, 2024, largely due to financing activities.
• The company completed a registered direct offering in August 2025, raising approximately $27.9 million in net proceeds.
• Zervimesine (CT1812) Phase 2 SHINE study in mild-to-moderate Alzheimer's disease met primary safety and tolerability endpoints, with a prespecified analysis showing a 95% reduction in cognitive decline in a p-tau217 biomarker subgroup, though overall cognitive benefit did not achieve statistical significance.
• Zervimesine Phase 2 SHIMMER study in mild-to-moderate Dementia with Lewy Bodies (DLB) met primary safety and tolerability endpoints, showing significant benefits across behavioral, functional, cognitive, and motor scales.
• Zervimesine Phase 2 MAGNIFY study in geographic atrophy (GA) secondary to dry AMD was voluntarily concluded, but showed 29% slower GA lesion growth and 28% smaller lesions at 18 months compared to placebo, with effects widening over time.
• The company believes its current cash and cash equivalents are sufficient to fund operations into the second quarter of 2027, excluding potential use of ATM or Lincoln Park financing.

Sentiment

Score: 7

Explanation: The company reported strong positive clinical data for zervimesine in DLB and promising results in GA, along with a significant capital raise that extended its cash runway. While the overall AD study did not hit statistical significance, the subgroup analysis provides a path forward. The financial position is strengthened, but the company remains unprofitable and will require further funding.

Positives

• Net loss significantly improved for the nine months ended September 30, 2025, decreasing by $5.985 million to $20.144 million.
• Cash and cash equivalents increased to $39.334 million as of September 30, 2025, from $25.009 million at December 31, 2024, strengthening liquidity.
• Successful completion of a registered direct offering in August 2025, raising approximately $27.890 million in net proceeds.
• Phase 2 SHIMMER study for DLB showed zervimesine-treated patients scored 86% better on neuropsychiatric inventory (NPIA-L), 52% better on ADCS-ADL, 91% better on CAF, and 62% better on UPDRS Part III compared to placebo, meeting primary safety and tolerability endpoints.
• Phase 2 MAGNIFY study for geographic atrophy, despite early conclusion, demonstrated 29% slower GA lesion growth and 28% smaller lesions at 18 months compared to placebo, with effects widening over time and no conversion to choroidal neovascularization.
• Phase 2 SHINE study for Alzheimer's disease met primary safety and tolerability endpoints, and a prespecified analysis identified a subgroup (plasma p-tau217 below median) with a 95% reduction in cognitive decline.
• Zervimesine was generally well tolerated across all three Phase 2 studies, with adverse events well balanced between treatment and placebo arms.
• An anonymous philanthropic donation was received to substantially fund an expanded access program (EAP) for people with DLB.

Negatives

• Overall cognitive benefit in the Phase 2 SHINE study for Alzheimer's disease did not achieve statistical significance, despite a 38% slowing of decline.
• Grant income decreased by $3.109 million to $13.407 million for the nine months ended September 30, 2025, compared to the prior year.
• The MAGNIFY study for geographic atrophy was voluntarily concluded early (January 2025) to reallocate resources, potentially indicating a shift in strategic focus away from this indication.
• The company continues to incur significant net losses and negative cash flows from operations, with an accumulated deficit of $195.304 million as of September 30, 2025.
• 23 incidents (9.6%) of transient treatment-emergent elevations in liver function tests (LFT) greater than 3xULN were observed across the three Phase 2 studies in zervimesine-treated participants, although these subsided after drug cessation.

Risks

• Ability to raise additional capital to fund operations and continue product candidate development.
• Ability to maintain the listing of common stock on the Nasdaq Capital Market.
• Estimates regarding expenses, future revenue, capital requirements, and needs for additional financing may be inaccurate.
• Challenges in successfully and timely advancing current and future product candidates through clinical trials, preclinical studies, and development activities.
• Uncertainty regarding the timing, scope, and likelihood of regulatory filings and approvals, including final regulatory approval.
• Ability to generate revenue from future product sales and achieve/maintain profitability.
• Impact of health epidemics, geopolitical turmoil (including global/regional conflicts), trade restrictions, social unrest, political instability, terrorism, or acts of war on business and clinical trials.
• Dependence on the success of zervimesine (CT1812), the lead product candidate.
• Challenges due to the novel approach of targeting the sigma-2 (S2R) receptor complex to treat age-related degenerative diseases.
• Success of competing therapies that are or become available.
• Ability to obtain and maintain regulatory clearance of IND applications for product candidates.
• Performance of third parties (CROs, suppliers, manufacturers) in connection with product development.
• Ability to attract and retain strategic collaborators with development, regulatory, and commercialization expertise.
• Ability to successfully commercialize product candidates and develop sales/marketing capabilities if approved.
• Size and growth of potential markets for product candidates and ability to serve them.
• Regulatory developments and approval pathways in the U.S. and foreign countries.
• Potential scope and value of intellectual property and proprietary rights, and ability to defend/enforce them without infringing third-party rights.
• Risks associated with global political changes and economic conditions, including inflation, tariffs, or uncertainty from political violence and unrest.
• Changes in funding for, or disruptions to the staffing and operations of the FDA and other government agencies (e.g., due to government shutdowns or new administrations) could hinder product development and approval.
• Potential for litigation, such as claims asserting violations of securities laws, which could be time-consuming and costly.

Future Outlook

The company expects to continue incurring significant and increasing expenses and net losses as it advances product candidates through development, seeks regulatory approval, expands its intellectual property, and operates as a public company. Substantial additional funding will be required to support continuing operations and growth, likely through equity offerings, debt financings, or collaborations. The company believes its current cash and cash equivalents, along with non-dilutive grants and recent financing, are sufficient to fund operations into the second quarter of 2027, assuming no usage of the remaining ATM or Lincoln Park Purchase Agreement funds. Future funding requirements are dependent on clinical trial progress, regulatory outcomes, and market conditions.

Management Comments

• "Our goal is to develop disease-modifying treatments for people with these degenerative disorders by initially leveraging our expertise in the sigma-2 (S2R) receptor, which is expressed by multiple cell types, including at neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina."
• "Data indicate that zervimesine antagonizes the binding and toxicity of amyloid beta oligomers via targeting the S2R complex and represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases."
• "Clinical results support this hypothesis, and our clinical trial findings provide evidence that the displacement of oligomers from synapses via zervimesine engagement with the S2R results in improved synapse function."
• "We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company."
• "We believe that our existing cash and cash equivalents, income from non-dilutive grants and donations, and net proceeds from our March 2024 follow-on public offering and August 2025 registered direct offering will be sufficient for us to fund our operating expenses and capital expenditures requirements into the second quarter of 2027, which assumes no usage from the remaining ATM nor the Lincoln Park Purchase Agreement."

Industry Context

Cognition Therapeutics operates in the highly competitive and challenging biopharmaceutical sector, specifically targeting age-related neurodegenerative diseases like Alzheimer's and DLB, and ophthalmic conditions like geographic atrophy. These areas represent significant unmet medical needs with limited approved therapies. The company's lead candidate, zervimesine, utilizes a novel sigma-2 receptor (S2R) complex targeting mechanism, differentiating it from many current approaches, particularly the monoclonal antibody treatments for Alzheimer's. The reported efficacy in DLB and GA, with oral administration, positions zervimesine as a potentially convenient alternative to existing or developing intravitreal or infused therapies, which often carry higher administration burdens or specific risks like CNV conversion in GA. The voluntary conclusion of the MAGNIFY study to focus resources on AD and DLB reflects a strategic prioritization common in biotech to optimize capital allocation towards programs with the highest perceived potential or closest to market.

Comparison to Industry Standards

• In Alzheimer's disease, the 38% slowing of cognitive decline (ADAS-Cog 11) in the overall SHINE study population is comparable in magnitude to results achieved with currently approved monoclonal antibody treatments, but with the added convenience of once-daily oral administration.
• For geographic atrophy, the 29% slower GA lesion growth and 28% smaller lesions observed with zervimesine are comparable to results reported with currently approved complement inhibitors. A key advantage noted is the convenience of once-daily oral administration and no observed conversion from dry AMD to choroidal neovascularization (CNV), a known risk factor with intravitreal complement inhibitors.

Legal Proceedings

• No pending legal actions that would have a material adverse effect on business and operations were reported as of September 30, 2025.
• The company may become involved in disputes or regulatory inquiries in the ordinary course of business, and as a public company, is susceptible to securities law litigation.

Stakeholder Impact

• Shareholders: Dilution from recent equity offerings (Registered Direct Offering, ATM sales) has occurred, but the capital raise has extended the cash runway, reducing immediate liquidity concerns. Future equity raises could lead to further dilution.
• Investors: Positive clinical trial results in DLB and GA, and a subgroup signal in AD, provide potential upside for the company's pipeline. However, the lack of statistical significance in the overall AD study and continued losses present ongoing risks.
• Employees: Continued research and development activities and potential expansion of the business may lead to additional hiring, benefiting employees. Equity-based compensation remains a component of employee remuneration.
• Patients (DLB, AD, GA): Zervimesine shows promise as a potential new treatment, particularly with its oral administration and favorable safety profile. The Expanded Access Program for DLB offers early access to eligible patients.
• Creditors: The improved cash position and extended runway reduce short-term credit risk.

Next Steps

• Advance current and future product candidates through preclinical and clinical development.
• Manufacture drug product and drug supply for ongoing and future trials.
• Seek regulatory approval for current and future product candidates.
• Maintain and expand the intellectual property portfolio.
• Hire additional research and development and business personnel.
• Continue the Phase 2 COG0203 (START) study, enrolling up to 540 participants with MCI or early AD.
• Operate the COG1202 (EAP) Expanded Access Program for DLB, initially accommodating approximately 30 individuals.
• Pursue additional non-dilutive research contributions or grants, including NIA grant funding.
• Potentially raise additional funding through public or private equity offerings, debt financings, or collaboration agreements.

Key Dates

Recommendation

Cognition Therapeutics has demonstrated promising clinical results for zervimesine in Dementia with Lewy Bodies (DLB) and Geographic Atrophy (GA), with the convenience of oral administration and a generally well-tolerated profile. The recent capital raise significantly improved the company's liquidity, extending its cash runway into Q2 2027. However, the Phase 2 Alzheimer's study, while showing a strong signal in a biomarker-defined subgroup, did not achieve statistical significance in the overall population, which introduces uncertainty for its lead indication. The company continues to incur substantial losses and will require further significant funding to bring any product to market. Given the mixed clinical outcomes in AD, the early termination of the GA study (despite positive data), and the ongoing need for capital, a 'hold' recommendation is appropriate. Investors should monitor the progress of the ongoing Phase 2 AD study (START) and any further development plans for DLB, as well as future financing activities, before considering a stronger position.

Keywords

Alzheimer's disease, Dementia with Lewy Bodies, Geographic Atrophy, zervimesine, CT1812, sigma-2 receptor, S2R, biopharmaceutical, clinical-stage, neurodegenerative, CNS, retina, Phase 2 clinical trials, drug development, SEC filing, 10-Q, biomarkers, p-tau217, capital raise, equity financing, NIA grants, Nasdaq